{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:37:28Z","timestamp":1792633048269,"version":"4.5.0"},"reference-count":213,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Non-alcoholic fatty liver disease (NAFLD) is a multisystem metabolic disorder, marked by abnormal lipid accumulation and intricate inter-organ interactions, which contribute to systemic metabolic imbalances. NAFLD may progress through several stages, including simple steatosis (NAFL), non-alcoholic steatohepatitis (NASH), cirrhosis, and potentially liver cancer. This disease is closely associated with metabolic disorders driven by overnutrition, with key pathological processes including lipid dysregulation, impaired lipid autophagy, mitochondrial dysfunction, endoplasmic reticulum (ER) stress, and local inflammation. While hepatic lipid metabolism in NAFLD is well-documented, further research into inter-organ communication mechanisms is crucial for a deeper understanding of NAFLD progression. This review delves into intrahepatic networks and tissue-specific signaling mediators involved in NAFLD pathogenesis, emphasizing their impact on distal organs.<\/jats:p>","DOI":"10.3389\/fendo.2024.1494560","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:10:58Z","timestamp":1736381458000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["Inter-organ metabolic interaction networks in non-alcoholic fatty liver disease"],"prefix":"10.3389","volume":"15","author":[{"given":"Yu-Hong","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongni","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongliang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.3350\/cmh.2022.0367","article-title":"MAFLD: How is it different from NAFLD","volume":"29","author":"Gofton","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.04.005","article-title":"Liver transplantation 2023: status report, current and future challenges","volume":"21","author":"Terrault","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"New Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J Hepatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac321","article-title":"Global prevalence and clinical characteristics of metabolic-associated fatty liver disease: A meta-analysis and systematic review of 10 739 607 individuals","volume":"107","author":"Chan","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2022.101344","article-title":"Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: A nationwide cohort study","volume":"48","author":"Jung","year":"2022","journal-title":"Diabetes Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.12.033","article-title":"The health impact of MAFLD, a novel disease cluster of NAFLD, is amplified by the integrated effect of fatty liver disease-related genetic variants","volume":"20","author":"Liu","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.13099","article-title":"The relationship between metabolic dysfunction-associated fatty liver disease and low muscle mass in an asymptomatic Korean population","volume":"13","author":"Seo","year":"2022","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2023.01.003","article-title":"Lipid disorders and metabolic-associated fatty liver disease","volume":"52","author":"Anwar","year":"2023","journal-title":"Endocrinol Metab Clinics North Am"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-021-00472-y","article-title":"Dietary carbohydrates and fats in nonalcoholic fatty liver disease","volume":"18","author":"Yki-J\u00e4rvinen","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1146\/annurev-nutr-062220-025831","article-title":"Dietary fructose and fructose-induced pathologies","volume":"42","author":"Jung","year":"2022","journal-title":"Annu Rev Nutr"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2021.09.010","article-title":"Molecular aspects of fructose metabolism and metabolic disease","volume":"33","author":"Herman","year":"2021","journal-title":"Cell Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2017.12.016","article-title":"The small intestine converts dietary fructose into glucose and organic acids","volume":"27","author":"Jang","year":"2018","journal-title":"Cell Metab"},{"key":"B17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jhep.2023.02.010","article-title":"Ketohexokinase-C regulates global protein acetylation to decrease carnitine palmitoyltransferase 1a-mediated fatty acid oxidation","volume":"79","author":"Helsley","year":"2023","journal-title":"J Hepatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"20220230","DOI":"10.1098\/rstb.2022.0230","article-title":"The fructose survival hypothesis for obesity","volume":"378","author":"Johnson","year":"2023","journal-title":"Philos Trans R Soc London Ser B Biol Sci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1172\/jci81993","article-title":"ChREBP regulates fructose-induced glucose production independently of insulin signaling","volume":"126","author":"Kim","year":"2016","journal-title":"J Clin Invest"},{"key":"B20","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.jhep.2014.05.023","article-title":"Homozygous MTTP and APOB mutations may lead to hepatic steatosis and fibrosis despite metabolic differences in congenital hypocholesterolemia","volume":"61","author":"Di Filippo","year":"2014","journal-title":"J Hepatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.009","article-title":"A new perspective on NAFLD: Focusing on lipid droplets","volume":"76","author":"Scorletti","year":"2022","journal-title":"J Hepatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/ame2.12327","article-title":"Perilipin 5 regulates hepatic stellate cell activation and high-fat diet-induced non-alcoholic fatty liver disease","volume":"7","author":"Yin","year":"2024","journal-title":"Anim Models Exp Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32756","article-title":"RIPK3 dampens mitochondrial bioenergetics and lipid droplet dynamics in metabolic liver disease","volume":"77","author":"Afonso","year":"2023","journal-title":"Hepatol (Baltimore Md)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-nutr-071813-105336","article-title":"Autophagy and lipid droplets in the liver","volume":"35","author":"Martinez-Lopez","year":"2015","journal-title":"Annu Rev Nutr"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nature07976","article-title":"Autophagy regulates lipid metabolism","volume":"458","author":"Singh","year":"2009","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2010.04.005","article-title":"Defective hepatic autophagy in obesity promotes ER stress and causes insulin resistance","volume":"11","author":"Yang","year":"2010","journal-title":"Cell Metab"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1080\/15548627.2019.1703355","article-title":"Sustained activation of autophagy suppresses adipocyte maturation via a lipolysis-dependent mechanism","volume":"16","author":"Zhang","year":"2020","journal-title":"Autophagy"},{"key":"B28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.tips.2021.11.011","article-title":"ER stress in obesity pathogenesis and management","volume":"43","author":"Ajoolabady","year":"2022","journal-title":"Trends Pharmacol Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.02.034","article-title":"Endoplasmic reticulum stress and the inflammatory basis of metabolic disease","volume":"140","author":"Hotamisligil","year":"2010","journal-title":"Cell"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.150272","article-title":"The ANGPTL3-4-8 model, a molecular mechanism for triglyceride trafficking","volume":"6","author":"Zhang","year":"2016","journal-title":"Open Biol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.64714","article-title":"Targeted Inhibition of LPL\/FABP4\/CPT1 fatty acid metabolic axis can effectively prevent the progression of nonalcoholic steatohepatitis to liver cancer","volume":"17","author":"Yang","year":"2021","journal-title":"Int J Biol Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2013.05.030","article-title":"High-fat diet induces changes in adipose tissue trans-4-oxo-2-nonenal and trans-4-hydroxy-2-nonenal levels in a depot-specific manner","volume":"63","author":"Long","year":"2013","journal-title":"Free Radic Biol Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2011.55","article-title":"Fatty liver is associated with impaired activity of PPAR\u03b3-coactivator 1\u03b1 (PGC1\u03b1) and mitochondrial biogenesis in mice","volume":"91","author":"Aharoni-Simon","year":"2011","journal-title":"Lab Investig J Tech Methods Pathol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000000375","article-title":"Membrane phospholipid remodeling modulates nonalcoholic steatohepatitis progression by regulating mitochondrial homeostasis","volume":"79","author":"Tian","year":"2024","journal-title":"Hepatol (Baltimore Md)"},{"key":"B35","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s11154-023-09850-0","article-title":"An update on the secretory functions of brown, white, and beige adipose tissue: Towards therapeutic applications","volume":"25","author":"Ghesmati","year":"2024","journal-title":"Rev Endocrine Metab Disord"},{"key":"B36","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s40001-023-01147-x","article-title":"Association between leptin and NAFLD: a two-sample Mendelian randomization study","volume":"28","author":"Guo","year":"2023","journal-title":"Eur J Med Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1210\/edrv.20.1.0357","article-title":"Interacting appetite-regulating pathways in the hypothalamic regulation of body weight","volume":"20","author":"Kalra","year":"1999","journal-title":"Endocrine Rev"},{"key":"B38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.14304\/surya.jpr.v6n3.2","article-title":"The role of leptin in maintaining plasma glucose during starvation","volume":"6","author":"Perry","year":"2018","journal-title":"Postdoc J"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/j.cmet.2022.09.020","article-title":"Leptin increases hepatic triglyceride export via a vagal mechanism in humans","volume":"34","author":"Metz","year":"2022","journal-title":"Cell Metab"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.3390\/ijms24021422","article-title":"Recent advances in the knowledge of the mechanisms of leptin physiology and actions in neurological and metabolic pathologies","volume":"24","author":"Casado","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.317453","article-title":"Hepatocyte-specific deletion of Janus kinase 2 (JAK2) protects against diet-induced steatohepatitis and glucose intolerance","volume":"287","author":"Shi","year":"2012","journal-title":"J Biol Chem"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2017.00030","article-title":"The leptin receptor complex: heavier than expected","volume":"8","author":"Wauman","year":"2017","journal-title":"Front Endocrinol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"16909","DOI":"10.3390\/ijms242316909","article-title":"Multi-organ increase in norepinephrine levels after central leptin administration and diet-induced obesity","volume":"24","author":"Fernandois","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.3390\/ijms18061321","article-title":"Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction","volume":"18","author":"Achari","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2009.02.131","article-title":"Adiponectin suppresses hepatic SREBP1c expression in an AdipoR1\/LKB1\/AMPK dependent pathway","volume":"382","author":"Awazawa","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/srep29423","article-title":"CHIP(-\/-)-mouse liver: adiponectin-AMPK-FOXO-activation overrides CYP2E1-elicited JNK1-activation, delaying onset of NASH: therapeutic implications","volume":"6","author":"Kim","year":"2016","journal-title":"Sci Rep"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00086.2010","article-title":"An APPL1-AMPK signaling axis mediates beneficial metabolic effects of adiponectin in the heart","volume":"299","author":"Fang","year":"2010","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/nm1557","article-title":"Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions","volume":"13","author":"Yamauchi","year":"2007","journal-title":"Nat Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"7162","DOI":"10.1038\/s41467-022-34931-0","article-title":"Sphingosine 1-phosphate mediates adiponectin receptor signaling essential for lipid homeostasis and embryogenesis","volume":"13","author":"Ruiz","year":"2022","journal-title":"Nat Commun"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2015.181","article-title":"Differential effects of leptin on adiponectin expression with weight gain versus obesity","volume":"40","author":"Singh","year":"2005","journal-title":"Int J Obes"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021808","article-title":"Serum resistin (FIZZ3) protein is increased in obese humans","volume":"88","author":"Degawa-Yamauchi","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2009.07.013","article-title":"The role of resistin as a regulator of inflammation: Implications for various human pathologies","volume":"133","author":"Filkov\u00e1","year":"2009","journal-title":"Clin Immunol (Orlando Fla)"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230x-14-39","article-title":"The relationship between hepatic resistin overexpression and inflammation in patients with nonalcoholic steatohepatitis","volume":"14","author":"Shen","year":"2014","journal-title":"BMC Gastroenterol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2011.01369.x","article-title":"Resistin: functional roles and therapeutic considerations for cardiovascular disease","volume":"165","author":"Jamaluddin","year":"2012","journal-title":"Br J Pharmacol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00431.2009","article-title":"Resistin decreases expression of endothelial nitric oxide synthase through oxidative stress in human coronary artery endothelial cells","volume":"299","author":"Chen","year":"2010","journal-title":"Am J Physiol Heart Circulatory Physiol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1590\/1806-9282.20231537","article-title":"The rs1862513 promoter variant of resistin gene influences susceptibility to nonalcoholic fatty liver disease","volume":"70","author":"Nouri","year":"2024","journal-title":"Rev da Associacao Med Bras (1992)"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1126\/science.3299706","article-title":"Severely impaired adipsin expression in genetic and acquired obesity","volume":"237","author":"Flier","year":"1987","journal-title":"Sci (New York NY)"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.2337\/dbi23-0005","article-title":"Adipose signals regulating distal organ health and disease","volume":"73","author":"Gilani","year":"2024","journal-title":"Diabetes"},{"key":"B59","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1038\/ncomms4485","article-title":"Endotrophin triggers adipose tissue fibrosis and metabolic dysfunction","volume":"5","author":"Sun","year":"2014","journal-title":"Nat Commun"},{"key":"B60","doi-asserted-by":"publisher","first-page":"e216","DOI":"10.1038\/emm.2016.4","article-title":"Emerging role of the brain in the homeostatic regulation of energy and glucose metabolism","volume":"48","author":"Roh","year":"2016","journal-title":"Exp Mol Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1126\/science.278.5335.135","article-title":"Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein","volume":"278","author":"Ollmann","year":"1997","journal-title":"Science"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2023.101839","article-title":"GPSM1 in POMC neurons impairs brown adipose tissue thermogenesis and provokes diet-induced obesity","volume":"79","author":"Tang","year":"2024","journal-title":"Mol Metab"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1096\/fj.05-3851com","article-title":"Targeted deletion of melanocortin receptor subtypes 3 and 4, but not CART, alters nutrient partitioning and compromises behavioral and metabolic responses to leptin","volume":"19","author":"Zhang","year":"2005","journal-title":"FASEB J"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mce.2005.04.012","article-title":"Molecular mechanisms of the neural melanocortin receptor dysfunction in severe early onset obesity","volume":"239","author":"Tao","year":"2005","journal-title":"Mol Cell Endocrinol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2007.318","article-title":"Role of adiponectin and inflammation in insulin resistance of Mc3r and Mc4r knockout mice","volume":"15","author":"Trevaskis","year":"2007","journal-title":"Obes (Silver Spring)"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.cmet.2024.02.010","article-title":"Age-related ciliopathy: Obesogenic shortening of melanocortin-4 receptor-bearing neuronal primary cilia","volume":"36","author":"Oya","year":"2024","journal-title":"Cell Metab"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2009.345","article-title":"Hypothalamic paraventricular nucleus lesion involvement in the sympathetic control of lipid mobilization","volume":"18","author":"Foster","year":"2010","journal-title":"Obes (Silver Spring)"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2023.101858","article-title":"A forebrain-hypothalamic ER stress driven circuit mediates hepatic steatosis during obesity","volume":"79","author":"Blackmore","year":"2024","journal-title":"Mol Metab"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-022-00566-0","article-title":"Astrocytic BDNF signaling within the ventromedial hypothalamus regulates energy homeostasis","volume":"4","author":"Ameroso","year":"2022","journal-title":"Nat Metab"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1002\/path.6204","article-title":"Brain-derived neurotrophic factor knock-out mice develop non-alcoholic steatohepatitis","volume":"261","author":"Ichimura-Shimizu","year":"2023","journal-title":"J Pathol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2014.02.007","article-title":"Central neural regulation of brown adipose tissue thermogenesis and energy expenditure","volume":"19","author":"Morrison","year":"2014","journal-title":"Cell Metab"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.121533","article-title":"Chemogenetic stimulation of the parasympathetic nervous system lowers hepatic lipid accumulation and inflammation in a nonalcoholic steatohepatitis mouse model","volume":"321","author":"Hur","year":"2023","journal-title":"Life Sci"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-018-1099-4","article-title":"Brain glucose-sensing mechanism and energy homeostasis","volume":"56","author":"L\u00f3pez-Gambero","year":"2019","journal-title":"Mol Neurobiol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.2337\/db12-1204","article-title":"Combination of obesity and high-fat feeding diminishes sensitivity to GLP-1R agonist exendin-4","volume":"62","author":"Duca","year":"2013","journal-title":"Diabetes"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.06.008","article-title":"Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease","volume":"69","author":"Lebeaupin","year":"2018","journal-title":"J Hepatol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"e12956","DOI":"10.1111\/jpi.12956","article-title":"Circadian desynchrony and glucose metabolism","volume":"76","author":"Speksnijder","year":"2024","journal-title":"J Pineal Res"},{"key":"B77","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/978-981-15-6082-8_5","article-title":"Circadian clock regulation on lipid metabolism and metabolic diseases","volume":"1276","author":"Pan","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1126\/science.1108750","article-title":"Obesity and metabolic syndrome in circadian Clock mutant mice","volume":"308","author":"Turek","year":"2005","journal-title":"Science"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-023-01435-w","article-title":"BMAL1 deletion protects against obesity and non-alcoholic fatty liver disease induced by a high-fat diet","volume":"48","author":"Zhan","year":"2024","journal-title":"Int J Obes"},{"key":"B80","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1210\/jc.2018-01171","article-title":"Ghrelin reduces TNF-\u03b1-induced human hepatocyte apoptosis, autophagy, and pyroptosis: role in obesity-associated NAFLD","volume":"104","author":"Ezquerro","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-011-0475-1","article-title":"Association of obestatin, ghrelin, and inflammatory cytokines in obese patients with non-alcoholic fatty liver disease","volume":"21","author":"Estep","year":"2011","journal-title":"Obes Surg"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2017.12.015","article-title":"Ghrelin regulation of glucose metabolism","volume":"100","author":"Poher","year":"2018","journal-title":"Peptides"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1007\/s13105-022-00933-1","article-title":"Molecular and cellular mechanisms underlying the hepatoprotective role of ghrelin against NAFLD progression","volume":"79","author":"Tuero","year":"2023","journal-title":"J Physiol Biochem"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvad071","article-title":"Antagonic effect of ghrelin and LEAP-2 on hepatic stellate cell activation and liver fibrosis in obesity-associated nonalcoholic fatty liver disease","volume":"188","author":"Ezquerro","year":"2023","journal-title":"Eur J Endocrinol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/dom.13385","article-title":"Role of ghrelin in pancreatic development and function","author":"Napolitano","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1159\/000464118","article-title":"Protective effects of glucagon-like peptide-1 analog on renal tubular injury in mice on high-fat diet","volume":"41","author":"Guo","year":"2017","journal-title":"Cell Physiol Biochem"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.600175","article-title":"Liraglutide alleviates hepatic steatosis and liver injury in T2MD rats via a GLP-1R dependent AMPK pathway","volume":"11","author":"Zhou","year":"2020","journal-title":"Front Pharmacol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101193","article-title":"Combination of an ACLY inhibitor with a GLP-1R agonist exerts additive benefits on nonalcoholic steatohepatitis and hepatic fibrosis in mice","volume":"4","author":"Desjardins","year":"2023","journal-title":"Cell Rep Med"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104684","article-title":"Combined GIP receptor and GLP1 receptor agonism attenuates NAFLD in male APOE\u22173-Leiden.CETP mice","volume":"93","author":"Ying","year":"2023","journal-title":"EBioMedicine"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1892","article-title":"Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes","volume":"43","author":"Hartman","year":"2020","journal-title":"Diabetes Care"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2016.11.009","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"41","author":"Dong","year":"2017","journal-title":"Clinics Res Hepatol Gastroenterol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"e15437","DOI":"10.1111\/dme.15437","article-title":"Glucose-lowering drugs and liver-related outcomes among individuals with type 2 diabetes: A systematic review of longitudinal population-based studies","volume":"41","author":"Khanmohammadi","year":"2024","journal-title":"Diabetic Med: J Br Diabetic Assoc"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C700130200","article-title":"Co-receptor requirements for fibroblast growth factor-19 signaling","volume":"282","author":"Wu","year":"2007","journal-title":"J Biol Chem"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.34.1885","article-title":"Fibroblast growth factor 19 treatment ameliorates disruption of hepatic lipid metabolism in farnesoid X receptor (Fxr)-null mice","volume":"34","author":"Miyata","year":"2011","journal-title":"Biol Pharm Bull"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22848","article-title":"Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease","volume":"49","author":"Miele","year":"2009","journal-title":"Hepatol (Baltimore Md)"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1080\/10408398.2021.1986466","article-title":"Gut microbiota and its metabolites: Bridge of dietary nutrients and obesity-related diseases","volume":"63","author":"Zhou","year":"2023","journal-title":"Crit Rev Food Sci Nutr"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1080\/10408398.2016.1245650","article-title":"Short-chain fatty acids in control of energy metabolism","volume":"58","author":"Hu","year":"2018","journal-title":"Crit Rev Food Sci Nutr"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-020-00804-9","article-title":"Targeting the alternative bile acid synthetic pathway for metabolic diseases","volume":"12","author":"Jia","year":"2021","journal-title":"Protein Cell"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1127743","article-title":"Gut microbiota derived bile acid metabolites maintain the homeostasis of gut and systemic immunity","volume":"14","author":"Su","year":"2023","journal-title":"Front Immunol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2023.07.011","article-title":"Hyodeoxycholic acid alleviates non-alcoholic fatty liver disease through modulating the gut-liver axis","volume":"35","author":"Kuang","year":"2023","journal-title":"Cell Metab"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.908011","article-title":"The role of gut microbiota-bile acids axis in the progression of non-alcoholic fatty liver disease","volume":"13","author":"Ni","year":"2022","journal-title":"Front Microbiol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2013.01.022","article-title":"Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease","volume":"268","author":"Lake","year":"2013","journal-title":"Toxicol Appl Pharmacol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2023.1121203","article-title":"Effects of cholesterol-lowering probiotics on non-alcoholic fatty liver disease in FXR gene knockout mice","volume":"10","author":"Yang","year":"2023","journal-title":"Front Nutr"},{"key":"B104","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1016\/j.cell.2024.03.034","article-title":"Gut symbionts alleviate MASH through a secondary bile acid biosynthetic pathway","volume":"187","author":"Nie","year":"2024","journal-title":"Cell"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i31.6965","article-title":"Mitochondrial DNA from hepatocytes as a ligand for TLR9: Drivers of nonalcoholic steatohepatitis","volume":"22","author":"Handa","year":"2016","journal-title":"World J Gastroenterol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106507","article-title":"Toll-like receptors and metabolic (dysfunction)-associated fatty liver disease","volume":"185","author":"Khanmohammadi","year":"2022","journal-title":"Pharmacol Res"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2022.2108655","article-title":"The double-edged sword of probiotic supplementation on gut microbiota structure in Helicobacter pylori management","volume":"14","author":"Nabavi-Rad","year":"2022","journal-title":"Gut Microbes"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2024.102336","article-title":"White adipose tissue in metabolic associated fatty liver disease","volume":"48","author":"Zhu","year":"2024","journal-title":"Clinics Res Hepatol Gastroenterol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-024-02335-9","article-title":"Hepatokines: unveiling the molecular and cellular mechanisms connecting hepatic tissue to insulin resistance and inflammation","volume":"61","author":"Miao","year":"2024","journal-title":"Acta Diabetol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/j.cmet.2018.03.014","article-title":"Evidence that TLR4 is not a receptor for saturated fatty acids but mediates lipid-induced inflammation by reprogramming macrophage metabolism","volume":"27","author":"Lancaster","year":"2018","journal-title":"Cell Metab"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2022.109953","article-title":"Obeticholic acid orchestrates the crosstalk between ileal autophagy and tight junctions in non-alcoholic steatohepatitis: Role of TLR4\/TGF-\u03b21 axis","volume":"361","author":"Tawfiq","year":"2022","journal-title":"Chemico-biol Interactions"},{"key":"B112","doi-asserted-by":"publisher","first-page":"e2300631","DOI":"10.1002\/ardp.202300631","article-title":"Exosomal miR-122, miR-128, miR-200, miR-298, and miR-342 as novel diagnostic biomarkers in NAFL\/NASH: Impact of LPS\/TLR-4\/FoxO3 pathway","volume":"357","author":"Samy","year":"2024","journal-title":"Archiv Der Pharmazie"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abe1692","article-title":"Hepatocyte TLR4 triggers inter-hepatocyte Jagged1\/Notch signaling to determine NASH-induced fibrosis","volume":"13","author":"Yu","year":"2021","journal-title":"Sci Trans Med"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175698","article-title":"Hydrogen inhalation ameliorates hepatic inflammation and modulates gut microbiota in rats with high-fat diet-induced non-alcoholic fatty liver disease","volume":"947","author":"Xue","year":"2023","journal-title":"Eur J Pharmacol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04467.x","article-title":"Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis","volume":"32","author":"Rakoski","year":"2010","journal-title":"Alimentary Pharmacol Ther"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13747","article-title":"Twenty-five-year trajectories of insulin resistance and pancreatic \u03b2-cell response and diabetes risk in nonalcoholic fatty liver disease","volume":"38","author":"VanWagner","year":"2018","journal-title":"Liver Int"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.30690","article-title":"Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association","volume":"35","author":"Pagano","year":"2002","journal-title":"Hepatol (Baltimore Md)"},{"key":"B118","doi-asserted-by":"publisher","first-page":"3139","DOI":"10.3390\/nu13093139","article-title":"Pancreatic \u03b2-cell dysfunction is associated with nonalcoholic fatty liver disease","volume":"13","author":"Chen","year":"2021","journal-title":"Nutrients"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.617400","article-title":"Amylin and calcitonin: potential therapeutic strategies to reduce body weight and liver fat","volume":"11","author":"Mathiesen","year":"2020","journal-title":"Front Endocrinol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.892672","article-title":"Contribution of liver and pancreatic islet crosstalk to \u03b2-cell function\/dysfunction in the presence of fatty liver","volume":"13","author":"L\u00f3pez-Bermudo","year":"2022","journal-title":"Front Endocrinol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1061682","article-title":"The relationship between glucose and the liver-alpha cell axis - A systematic review","volume":"13","author":"Pixner","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-020-05334-x","article-title":"The liver-alpha cell axis associates with liver fat and insulin resistance: a validation study in women with non-steatotic liver fat levels","volume":"64","author":"Gar","year":"2021","journal-title":"Diabetologia"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101080","article-title":"Glucagon acutely regulates hepatic amino acid catabolism and the effect may be disturbed by steatosis","volume":"42","author":"Winther-S\u00f8rensen","year":"2020","journal-title":"Mol Metab"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1149233","article-title":"The roles of hepatokine and osteokine in liver-bone crosstalk: Advance in basic and clinical aspects","volume":"14","author":"Li","year":"2023","journal-title":"Front Endocrinol"},{"key":"B125","doi-asserted-by":"publisher","first-page":"16009","DOI":"10.1038\/boneres.2016.9","article-title":"TGF-\u03b2 and BMP signaling in osteoblast, skeletal development, and bone formation, homeostasis and disease","volume":"4","author":"Wu","year":"2016","journal-title":"Bone Res"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-022-00620-x","article-title":"BMP4 and Gremlin 1 regulate hepatic cell senescence during clinical progression of NAFLD\/NASH","volume":"4","author":"Baboota","year":"2022","journal-title":"Nat Metab"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1007\/s13679-024-00586-9","article-title":"Osteokines in nonalcoholic fatty liver disease","volume":"13","author":"Vachliotis","year":"2024","journal-title":"Curr Obes Rep"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-020-0214-9","article-title":"Bone morphogenetic protein 8B promotes the progression of non-alcoholic steatohepatitis","volume":"2","author":"Vacca","year":"2020","journal-title":"Nat Metab"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.605967","article-title":"The role of bone morphogenetic protein 9 in nonalcoholic fatty liver disease in mice","volume":"11","author":"Sun","year":"2020","journal-title":"Front Pharmacol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M078980","article-title":"Osteopontin regulates the cross-talk between phosphatidylcholine and cholesterol metabolism in mouse liver","volume":"58","author":"Nu\u00f1ez-Garcia","year":"2017","journal-title":"J Lipid Res"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202405678","article-title":"OPN-mediated crosstalk between hepatocyte E4BP4 and hepatic stellate cells promotes MASH-associated liver fibrosis","volume":"29","author":"Wang","year":"2024","journal-title":"Adv Sci (Weinheim Baden-Wurttemberg Germany)"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.03.228","article-title":"Macrophage-derived osteopontin (SPP1) protects from nonalcoholic steatohepatitis","volume":"165","author":"Han","year":"2023","journal-title":"Gastroenterology"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31582","article-title":"Osteopontin takes center stage in chronic liver disease","volume":"73","author":"Song","year":"2021","journal-title":"Hepatol (Baltimore Md)"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1138078","article-title":"Vitamin D improves hepatic steatosis in NAFLD via regulation of fatty acid uptake and \u03b2-oxidation","volume":"14","author":"Du","year":"2023","journal-title":"Front Endocrinol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.3390\/molecules29061401","article-title":"Vitamin D mitigates hepatic fat accumulation and inflammation and increases SIRT1\/AMPK expression in AML-12 hepatocytes","volume":"29","author":"Chang","year":"2024","journal-title":"Mol (Basel Switzerland)"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1164512","article-title":"Vitamin D3 alleviates nonalcoholic fatty liver disease in rats by inhibiting hepatic oxidative stress and inflammation via the SREBP-1-c\/PPAR\u03b1-NF-\u03baB\/IR-S2 signaling pathway","volume":"14","author":"Reda","year":"2023","journal-title":"Front Pharmacol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1039\/d4fo00215f","article-title":"Vitamin D(3) exacerbates steatosis while calcipotriol inhibits inflammation in non-alcoholic fatty liver disease in Sod1 knockout mice: a comparative study of two forms of vitamin D","volume":"15","author":"Yang","year":"2024","journal-title":"Food Funct"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-023-01125-7","article-title":"Vitamin D ameliorates age-induced nonalcoholic fatty liver disease by increasing the mitochondrial contact site and cristae organizing system (MICOS) 60 level","volume":"56","author":"Kim","year":"2024","journal-title":"Exp Mol Med"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1149967","article-title":"The effect of high oral loading dose of cholecalciferol in non-alcoholic fatty liver disease patients. A randomized placebo controlled trial","volume":"14","author":"Mohamed","year":"2023","journal-title":"Front Pharmacol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202308_33413","article-title":"A randomized placebo-controlled, double-blind study to investigate the effect of a high oral loading dose of cholecalciferol in non-alcoholic fatty liver disease patients, new insights on serum STAT-3 and hepassocin","volume":"27","author":"Alarfaj","year":"2023","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1215790","article-title":"Causal association of NAFLD with osteoporosis, fracture and falling risk: a bidirectional Mendelian randomization study","volume":"14","author":"Cui","year":"2023","journal-title":"Front Endocrinol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-022-06459-y","article-title":"Relationship between prevalence and risk of osteoporosis or osteoporotic fracture with non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"33","author":"Pan","year":"2022","journal-title":"Osteoporosis Int"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10714","article-title":"Are nonalcoholic fatty liver disease and bone mineral density associated? - A cross-sectional study using liver biopsy and dual-energy X-ray absorptiometry","volume":"7","author":"Hansen","year":"2023","journal-title":"JBMR Plus"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-022-07563-z","article-title":"Histologic severity of nonalcoholic fatty liver disease associates with reduced bone mineral density in children","volume":"68","author":"Khan","year":"2023","journal-title":"Digest Dis Sci"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-024-03724-4","article-title":"The relationship between advanced liver fibrosis and osteoporosis in type 2 diabetes patients with MAFLD","volume":"85","author":"Pan","year":"2024","journal-title":"Endocrine"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.825448","article-title":"Prevalence and trends in low bone density, osteopenia and osteoporosis in U.S. Adults with non-alcoholic fatty liver disease, 2005-2014","volume":"12","author":"Zhai","year":"2021","journal-title":"Front Endocrinol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1016\/j.exger.2024.112638","article-title":"Distribution and diagnostic modeling of osteoporosis and comorbidities across demographic factors: A cross-sectional study of 2224 female patients","volume":"198","author":"Dingpeng","year":"2024","journal-title":"Exp Gerontol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-022-10461-1","article-title":"Liver fibrosis is associated with impaired bone mineralization and microstructure in obese individuals with non-alcoholic fatty liver disease","volume":"17","author":"Barchetta","year":"2023","journal-title":"Hepatol Int"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1278505","article-title":"Associations of metabolic dysfunction-associated fatty liver disease and hepatic fibrosis with bone mineral density and risk of osteopenia\/osteoporosis in T2DM patients","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Endocrinol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4862","article-title":"Nonalcoholic fatty liver disease is associated with decreased bone mineral density in adults: A systematic review and meta-analysis","volume":"38","author":"Su","year":"2023","journal-title":"J Bone Mineral Res"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.857110","article-title":"Relationship between non-alcoholic fatty liver disease and degree of hepatic steatosis and bone mineral density","volume":"13","author":"Xie","year":"2022","journal-title":"Front Endocrinol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-024-01204-5","article-title":"The impact of non-alcohol fatty liver disease on bone mineral density is mediated by sclerostin by mendelian randomization study","volume":"114","author":"Liu","year":"2024","journal-title":"Calcified Tissue Int"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.01.010","article-title":"Associations of muscle mass and grip strength with severe NAFLD: A prospective study of 333,295 UK Biobank participants","volume":"76","author":"Petermann-Rocha","year":"2022","journal-title":"J Hepatol"},{"key":"B154","doi-asserted-by":"publisher","first-page":"891","DOI":"10.3390\/nu15040891","article-title":"Impact of sarcopenia on non-alcoholic fatty liver disease","volume":"15","author":"Iwaki","year":"2023","journal-title":"Nutrients"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12212","article-title":"Elevated serum myostatin level is associated with worse survival in patients with liver cirrhosis","volume":"8","author":"Nishikawa","year":"2017","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2023.155676","article-title":"Sarcopenia, sarcopenic obesity and nonalcoholic fatty liver disease","volume":"147","author":"Polyzos","year":"2023","journal-title":"Metabolism"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-019-4927-9","article-title":"Myokines in metabolic homeostasis and diabetes","volume":"62","author":"Eckel","year":"2019","journal-title":"Diabetologia"},{"key":"B158","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.3390\/cells10123306","article-title":"Exercise-induced irisin decreases inflammation and improves NAFLD by competitive binding with MD2","volume":"10","author":"Zhu","year":"2021","journal-title":"Cells"},{"key":"B159","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.cmet.2013.12.003","article-title":"[amp]]beta;-Aminoisobutyric acid induces browning of white fat and hepatic \u03b2-oxidation and is inversely correlated with cardiometabolic risk factors","volume":"19","author":"Roberts","year":"2014","journal-title":"Cell Metab"},{"key":"B160","doi-asserted-by":"publisher","first-page":"E297","DOI":"10.1152\/ajpendo.00353.2017","article-title":"Do skeletal muscle-secreted factors influence the function of pancreatic \u03b2-cells","volume":"314","author":"Barlow","year":"2018","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2020.101635","article-title":"Exercise and dietary intervention ameliorate high-fat diet-induced NAFLD and liver aging by inducing lipophagy","volume":"36","author":"Gao","year":"2020","journal-title":"Redox Biol"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1172\/jci23606","article-title":"FGF-21 as a novel metabolic regulator","volume":"115","author":"Kharitonenkov","year":"2005","journal-title":"J Clin Invest"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1016\/j.imr.2014.09.007","article-title":"Exercise-induced myokines in health and metabolic diseases","volume":"3","author":"So","year":"2014","journal-title":"Integr Med Res"},{"key":"B164","doi-asserted-by":"publisher","first-page":"6047","DOI":"10.1038\/s41467-023-41832-3","article-title":"Metabolic crosstalk between skeletal muscle cells and liver through IRF4-FSTL1 in nonalcoholic steatohepatitis","volume":"14","author":"Guo","year":"2023","journal-title":"Nat Commun"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1111\/obr.12567","article-title":"Interleukin-15 in obesity and metabolic dysfunction: current understanding and future perspectives","volume":"18","author":"Duan","year":"2017","journal-title":"Obes Rev"},{"key":"B166","doi-asserted-by":"publisher","first-page":"5370","DOI":"10.1038\/s41598-022-09174-0","article-title":"Aerobic exercise promotes the expression of ATGL and attenuates inflammation to improve hepatic steatosis via lncRNA SRA","volume":"12","author":"Wu","year":"2022","journal-title":"Sci Rep"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15989","article-title":"Improvement in histological endpoints of MAFLD following a 12-week aerobic exercise intervention","volume":"52","author":"O\u2019Gorman","year":"2020","journal-title":"Alimentary Pharmacol Ther"},{"key":"B168","doi-asserted-by":"publisher","first-page":"9427","DOI":"10.3390\/ijms23169427","article-title":"Resistance training improves beta cell glucose sensing and survival in diabetic models","volume":"23","author":"Bronczek","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B169","doi-asserted-by":"publisher","first-page":"15475","DOI":"10.1038\/s41598-023-42687-w","article-title":"Effect of functional resistance training on the structure and function of the heart and liver in patients with non-alcoholic fatty liver","volume":"13","author":"Jafarikhah","year":"2023","journal-title":"Sci Rep"},{"key":"B170","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/metabo13010014","article-title":"HIIT ameliorates inflammation and lipid metabolism by regulating macrophage polarization and mitochondrial dynamics in the liver of type 2 diabetes mellitus mice","volume":"13","author":"Wang","year":"2022","journal-title":"Metabolites"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-022-07779-z","article-title":"High-intensity interval training is safe, feasible and efficacious in nonalcoholic steatohepatitis: A randomized controlled trial","volume":"68","author":"Keating","year":"2023","journal-title":"Digest Dis Sci"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad827","article-title":"Aerobic, resistance, or combined exercise training and cardiovascular risk profile in overweight or obese adults: the CardioRACE trial","volume":"45","author":"Lee","year":"2024","journal-title":"Eur Heart J"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2024.2428432","article-title":"Effect of different training modalities on lipid metabolism in patients with type ii diabetes mellitus: a network meta-analysis","volume":"56","author":"Xing","year":"2024","journal-title":"Ann Med"},{"key":"B174","doi-asserted-by":"publisher","first-page":"6212","DOI":"10.1038\/s41598-024-51470-4","article-title":"Effect of different exercise modalities on nonalcoholic fatty liver disease: a systematic review and network meta-analysis","volume":"14","author":"Xue","year":"2024","journal-title":"Sci Rep"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2023-330110","article-title":"Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis","volume":"72","author":"En Li Cho","year":"2023","journal-title":"Gut"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-021-00519-y","article-title":"Association of metabolic dysfunction-associated fatty liver disease with kidney disease","volume":"18","author":"Wang","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15931","article-title":"MAFLD predicts cardiovascular disease risk better than MASLD","volume":"44","author":"Pan","year":"2024","journal-title":"Liver Int"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1161402","article-title":"Liver-bone crosstalk in non-alcoholic fatty liver disease: Clinical implications and underlying pathophysiology","volume":"14","author":"Zhao","year":"2023","journal-title":"Front Endocrinol"},{"key":"B179","doi-asserted-by":"publisher","first-page":"8445","DOI":"10.3390\/ijms24098445","article-title":"Non-alcoholic fatty liver disease and bone tissue metabolism: current findings and future perspectives","volume":"24","author":"Drapkina","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B180","doi-asserted-by":"publisher","first-page":"6409","DOI":"10.1038\/s41467-023-42162-0","article-title":"ZSP1601, a novel pan-phosphodiesterase inhibitor for the treatment of NAFLD, A randomized, placebo-controlled phase Ib\/IIa trial","volume":"14","author":"Hu","year":"2023","journal-title":"Nat Commun"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32742","article-title":"Fibroblast growth factor receptor 1\/Klotho\u03b2 agonist BFKB8488A improves lipids and liver health markers in patients with diabetes or NAFLD: A phase 1b randomized trial","volume":"78","author":"Wong","year":"2023","journal-title":"Hepatol (Baltimore Md)"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(22)00347-8","article-title":"Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b\/2a multiple-ascending-dose study","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B183","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"New Engl J Med"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02427-z","article-title":"The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial","volume":"29","author":"Bhatt","year":"2023","journal-title":"Nat Med"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.06.003","article-title":"Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon\/glucagon-like peptide-1 receptor dual agonist, in cirrhosis","volume":"81","author":"Lawitz","year":"2024","journal-title":"J Hepatol"},{"key":"B186","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s13046-022-02383-5","article-title":"A first-in-human phase 1\/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors","volume":"41","author":"Chan","year":"2022","journal-title":"J Exp Clin Cancer Res: CR"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1097\/hc9.0000000000000276","article-title":"Safety and pharmacokinetics of BI 685509, a soluble guanylyl cyclase activator, in patients with cirrhosis: A randomized Phase Ib study","volume":"7","author":"Lawitz","year":"2023","journal-title":"Hepatol Commun"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2023.2264850","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of a novel farnesoid X receptor (FXR) agonist-TQA3526 in healthy Chinese volunteers: a double-blind, randomized, placebo-controlled, dose-escalation, food effect phase I study","volume":"55","author":"Xu","year":"2023","journal-title":"Ann Med"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13453","article-title":"EDP-297: A novel, farnesoid X receptor agonist-Results of a phase I study in healthy subjects","volume":"16","author":"Marotta","year":"2023","journal-title":"Clin Trans Sci"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(23)00272-8","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"8","author":"Harrison","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.10.023","article-title":"Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH","volume":"78","author":"Ratziu","year":"2023","journal-title":"J Hepatol"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(22)00017-6","article-title":"Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2\/3): a randomised, double-blind, placebo-controlled, phase 2b trial","volume":"7","author":"Harrison","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.05.013","article-title":"A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease","volume":"79","author":"Romero-G\u00f3mez","year":"2023","journal-title":"J Hepatol"},{"key":"B194","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41591-022-02200-8","article-title":"Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a\/b trial","volume":"29","author":"Sanyal","year":"2023","journal-title":"Nat Med"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01861-9","article-title":"Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study","volume":"28","author":"Harrison","year":"2022","journal-title":"Nat Med"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(24)00246-2","article-title":"Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Loomba","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B197","doi-asserted-by":"publisher","first-page":"e056159","DOI":"10.1136\/bmjopen-2021-056159","article-title":"Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study","volume":"12","author":"Amin","year":"2022","journal-title":"BMJ Open"},{"key":"B198","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1111\/dom.14946","article-title":"A phase 2a, randomized, double-blind, placebo-controlled, three-arm, parallel-group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF-06835919 in patients with non-alcoholic fatty liver disease and type 2 diabetes","volume":"25","author":"Saxena","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.04.003","article-title":"Cenicriviroc lacked efficacy to treat liver fibrosis in nonalcoholic steatohepatitis: AURORA phase III randomized study","volume":"22","author":"Anstee","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B200","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1016\/j.cgh.2021.07.020","article-title":"Obeticholic acid impact on quality of life in patients with nonalcoholic steatohepatitis: REGENERATE 18-month interim analysis","volume":"20","author":"Younossi","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000000723","article-title":"Artificial intelligence scoring of liver biopsies in a phase II trial of semaglutide in nonalcoholic steatohepatitis","volume":"80","author":"Ratziu","year":"2024","journal-title":"Hepatol (Baltimore Md)"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1111\/apt.18331","article-title":"Semaglutide 2.4\u2009mg in participants with metabolic dysfunction-associated steatohepatitis: baseline characteristics and design of the phase 3 ESSENCE trial","volume":"60","author":"Newsome","year":"2024","journal-title":"Alimentary Pharmacol Ther"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2022-002950","article-title":"Effect of progressive resistance training with weight loss compared with weight loss alone on the fatty liver index in older adults with type 2 diabetes: secondary analysis of a 12-month randomized controlled trial","volume":"10","author":"Freer","year":"2022","journal-title":"BMJ Open Diabetes Res Care"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.04.003","article-title":"Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial","volume":"77","author":"Alkhouri","year":"2022","journal-title":"J Hepatol"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.02.022","article-title":"Safety and efficacy of efruxifermin in combination with a GLP-1 receptor agonist in patients with NASH\/MASH and type 2 diabetes in a randomized phase 2 study","volume":"23","author":"Harrison","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2024.101398","article-title":"A prospective randomised comparative four-arm intervention study of efficacy and safety of saroglitazar and vitamin E in patients with non-alcoholic fatty liver disease (NAFLD)\/non-alcoholic steatohepatitis (NASH)-SVIN TRIAL","volume":"14","author":"Mir","year":"2024","journal-title":"J Clin Exp Hepatol"},{"key":"B208","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.cmet.2022.12.001","article-title":"Effect of alternate day fasting combined with aerobic exercise on non-alcoholic fatty liver disease: A randomized controlled trial","volume":"35","author":"Ezpeleta","year":"2023","journal-title":"Cell Metab"},{"key":"B209","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.3390\/nu15061398","article-title":"Alternate-day fasting combined with exercise: effect on sleep in adults with obesity and NAFLD","volume":"15","author":"Ezpeleta","year":"2023","journal-title":"Nutrients"},{"key":"B210","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1038\/s41467-022-29968-0","article-title":"A randomized controlled trial for response of microbiome network to exercise and diet intervention in patients with nonalcoholic fatty liver disease","volume":"13","author":"Cheng","year":"2022","journal-title":"Nat Commun"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0302155","article-title":"Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial","volume":"19","author":"Lin","year":"2024","journal-title":"PloS One"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1993","article-title":"Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial","volume":"6","author":"Yoneda","year":"2022","journal-title":"Hepatol Commun"},{"key":"B213","article-title":"Ten-hour intermittent fasting plus mediterranean diet versus mediterranean diet alone for treatment of nonalcoholic fatty liver disease (NAFLD)","volume":"163","author":"Milgrom","year":"2024","journal-title":"Harefuah"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1494560\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:11:08Z","timestamp":1736381468000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1494560\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":213,"alternative-id":["10.3389\/fendo.2024.1494560"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2024.1494560","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,9]]},"article-number":"1494560"}}